Scalable Bioreactor Solutions
For Shear-Sensitive Cell Cultures
From Lab to Industrial Scale
From research to industrial production
for multiple cell types
Stem cells, immune cells, organoids, microalgae…
Industrial-Scale Cell Solutions
for Advanced Bioproduction
Scaling, our cutting-edge bioreactor technology eliminates shear stress, ensuring optimal cell growth for cell therapy and cultivated meat production.
Technology
for the Future of
Bioproduction
Few solutions have succeeded in truly overcoming the core limitations of traditional bioreactor systems — especially when it comes to producing fragile cells at industrial scale. Cellura takes a different path.
Our patented rotating bioreactor technology is designed to break through the major barriers of cell culture, particularly shear stress, which has long compromised the viability and function of sensitive cells. Our approach delivers both scalable manufacturing capabilities and high- performance tools for research environments.
From stem cells, organoids, NK, T cells to microalgae and rare cell lines, Cellura’s innovation is powering the next generation of bioproduction across medicine, biotechnology, and sustainable food.
Scalability
Designed for seamless integration in cell therapy & cultivated meat production.
Optimized Mixing Efficiency
Achieves homogeneous gas, nutrient, and cell distribution.
Minimal Shear Stress
Protects fragile cells from mechanical damage.
Effortless 3D Cell Expansion
Our innovation is the ultimate low-shear, cost-effective solution for transitioning from traditional 2D flask culture to advanced 3D bioreactor systems—without disrupting your current workflow.
Latest Insights & Innovations
Stay updated with our lastest news in bioproduction
Cellura is proud to announce its participation in the BIO International Convention 2025, taking place from June 16 to 19, 2025 at the Boston Convention & Exhibition Center (BCEC). This…
Regenerative medicine is a rapidly evolving field offering promising prospects for treating chronic and degenerative diseases. However, equitable access to these innovative therapies remains a significant challenge—largely due to high…
The large-scale production of monoclonal antibodies (mAbs) is essential to meet the growing demand for targeted therapies. Recent advances in bioreactor design have significantly improved efficiency, scalability, and product quality—…
